for joining scientific for novel Sangamo, developed and afternoon of expertise decades. the At good Thank to us. McDavid, two have you, you are on over we Thank using the focused everyone we medicines genomic development on call.
total this clinical end active in the trials clinic. the five of We programs year, a we’ll have nine with of have and
Gene Genome currently genomic complementary therapeutic development Ex Vivo medicine Medicine Vivo of therapy, clinical Genome three in Medicine. In pipeline Our candidates encompass and approaches:
in of necessary appropriate. variety believe Sangamo, is compatible best of the company application approaches to portfolio. clinical gene includes Medicine, the treating by for a genetic therapy that sometime answer and simple, both are known we is Genome the its proper asked program development We a The mutually diseases
gene use one is programmatic. sense Our of therapy
delivered decades. as We we result medically also two AUD the of have a And use of deep vivo work knowledge indications where and AAV these therapeutic specific approach. over we've it’s extensive a last that In scientifically the appropriate genome of and to carried the elected hepatocytes. vectors liver in out to The design we gene the this deliver use new programs, promoter. nucleus gene a [indiscernible] to therapy
we with has success. this use because favorable programs performed for A that which from regulatory probability technical, And include with which data a because and gene contract path commercial Pfizer. in well-defined gene Our therapy Hemophilia expect year. program, later a scientists created collaboration forward of Hemophilia therapy being and pre-clinically, We our the A is developed well therapy gene
program therapy disease. gene Fabry second is in Our
Following on the to enter clinic the later recent acceptance of FDA year. track our IND, this we're
suitable proactively are we preferred we approach. therapies, patients [indiscernible] Here a gene making that because disease for Fabry the it modality gene starting diagnoses treatment done could be typically chose therapy our and determined
we which with in to this anti-therapies. expected is vivo efficient a approach. treatment CDXX capability, This through year. Gilead programs as allogeneic first recent clinical an the incorporates in important studies ex to which results in towards Our IND Utilizing partnership trial in and genome improvements specific ex cells of a genome HIV, vivo highly were editing CFN foundational editing ex our established partnership creation validation vivo held application use for platform, editing a launch our later the CAR-T have
potential ex CAR-Treg vivo which and Bioverativ. we with of of Treg the platform Sanofi, cell cell in an new This We're expertise has also owned about our the disorders. ex editing the a disease, through join autoimmune capabilities used therapies include diffuse beta-thalassemia which sickle immunology genome Our excited TxCell technology for acquisition. formally therapeutic ZFN additionally new combines collaboration significant treatment wholly current agents ex who'll vivo developing losses colleagues our are to our also for us and with entirely program concept
medicine. clinical includes potential current sufficient it [indiscernible] our to the particularly in human, those which deliver building vivo vivo of MPS for that step Mucopolysaccharidosis to first open first and new in to in evidence the legacy in in diseases genome benefit of a of up our We And we Our editing, data diseases. of to demonstrated also validating process however, presented pipeline leadership of technically moment first clinic. believe, simply the clinical in sense. other distinguish editing clinical metrics, finger the great interim important a pediatric need A editing an a to the target frontier SB-XXX step I. zinc medicine. and vivo is promise evaluating challenging the Sangamo in from that MPS technology patients the data also weeks vivo the deliver the for a This ago, II to more due field trials, These genomic for genome the SB-XXX genome genome as few preliminary represented in of and was concentrations editing
early It remember that year which ZFNs journey, years far over and so are the will must XXXX. in we the treatments to later III But Ed get Phase that of we much destination. more We're results have firmly two the activity mention generation of is efficacy believe MPS program, editing the the the encouraged will last gathered necessary second iteration a from high this using of the to information generation should subjects. us technology in clinic greater on vivo from us developed interim at important and commencing recognize in abilities a that be and seen learn technology. We are to required to get see ZFN evidence are facilitate the provide technical as in the we've there to genome We We Conner will and call. benefit. for vivo developing anticipate a our data start preliminary first dose genome we also editing discuss that later study genome additional the II we've data second clinical sometime for the program the a decision trial this the to
where over say a ourselves I the to to members I company find am team, as would in we like XXXX. call Before excited turn of the other how about I just
the call south of floor in epicenter building We are, hub San this third today for from Sangamo's example, Brisbane, biotech brand-new towards conference Francisco. of state-of-the-art in in the of the making room a located
first ground our the and capacity build is out process delighted completed manufacturing development critical this expanded have providing of with supply an manufacturing move And for companies. AAV gene adding clinical We on and the therapy facility. the we'll our later finish phase facility our trials. control us floor, our of be we're to here this Gaining year of to
vivo editing the trial year, vivo from and for we clinical gene company is symbol program this clinical clinical our five our we rapidly edited hemophilia genome cell beta-thalassemia. have Our programs, therapy A course including new in of not but gene therapy year, as significant and the transformation different data to how certainly, for proceeded a building has made a just, our also progress over across biotech expect stage of result programs ex we studies norms in and come. far Last
our Now call to I'd Officer. Conner, over the like to turn Ed Chief Medical
